Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro

Journal of Infectious Diseases

Volumn 172, Issue 2, 1995, Pages 380-388

  Campbell, Martin C ^a,b   Swart, Pieter J ^a,b   Béthune, Marie Pierre De ^a,b,c   Pauwels, Rudi ^a,b,c   Clercq, Erik De ^a,b   The, T Bauw ^a,b   Meijer, Dirk K F ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITIC ACID; ALPHA LACTALBUMIN; ASIALOFETUIN; BETA LACTOGLOBULIN; DEXTRAN SULFATE; FERRIC CHLORIDE; HUMAN SERUM ALBUMIN; LACTOFERRIN; LYSOZYME; MILK PROTEIN; MONOCLONAL ANTIBODY; NEOGLYCOPROTEIN; OROSOMUCOID; PLASMA PROTEIN; POLYLYSINE; SUCCINIC ANHYDRIDE; TRANSFERRIN;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; COLOSTRUM; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOPATHOGENIC EFFECT; DRUG POTENCY; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN PURIFICATION; VIRUS ADSORPTION; VIRUS INHIBITION;

ANIMAL; BLOOD PROTEINS; CATTLE; CELLS, CULTURED; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOPATHOGENIC EFFECT, VIRAL; DNA REPLICATION; EMBRYO; FEMALE; FIBROBLASTS; GLYCOPROTEINS; HIV-1; HUMAN; LACTOFERRIN; LUNG; MILK PROTEINS; PREGNANCY; SUPPORT, NON-U.S. GOV'T; VIRUS INHIBITORS; VIRUS REPLICATION;

EID: 0029080953     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/172.2.380     Document Type: Article

References (55)

1. Plummer G. Cytomegaloviruses of man and animals. Prog Med Virol 1973;9:302-40.
2. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med 1971;285:203-14.
3. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II. N Engl J Med 1971;285:267-74.
4. Skolnik PR, Kosloff BR, Hirsch MS. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 1988;157:508-14.
5. Davis MG, Kenney SC, Kamine J, Pagano JS, Huang ES. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sei USA 1987; 84:8642-6.
6. Drew WL, Mintz L, Miner RC, Sands M, Kettener B. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis 1981; 143:188-92.
7. Bowden RA. Antivirals for cytomegalovirus. In: Michelson S, Plotkin SA, eds. Multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Exerpta Medica, 1993:241-9.
8. Azad RF, Driver VB, Tanaka K, Crooke RM, Anderson KP. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimi-crob Agents Chemother 1993;37:1945-54.
9. Bryant LA, Sinclair JH. Inhibition of human cytomegalovirus major immediate early gene expression by antisense RNA expression vectors. J Gen Virol 1993;74:1965-7.
10. Snoeck R, Neyts J, De Clercq E. Strategies for the treatment of cytomegalovirus infections. In: Michelson S, Plotkin SA, eds. Multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Exerpta Medica, 1993:269-78.
11. Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E, Meijer DKF. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol Pharmacol 1991;39:818-23.
12. Jansen RW, Schols D, Pauwels R, De Clercq E, Meijer DKF. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993;44:1003-7.
13. Matthews THJ, Nair CDG, Lawrence MK, Tyrrell DAJ. Antiviral activity in milk of possible clinical importance. Lancet 1976;2:1387-9.
14. Bullen JJ, Armstrong JA. The role of lactoferrin in the bactericidal function of polymorphonuclear leucocytes. Immunology 1979;36:781-91.
15. Bellamy WR. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992;73:472-9.
16. Yamauchi K. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun 1993;61:719-28.
17. Bellamy WR. Role of cell-binding in the antibacterial mechanism of lactoferricin B. J Appl Bacteriol 1993;75:478-84.
18. Bellamy WR. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol (Berl) 1993;182:97-105.
19. Nikawa H. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol 1993;38:1057-63.
20. Wolach B, Coates TD, Hugh TE, Baehner RL, Boxer LA. Plasma lactoferrin reflects granulocyte activation via complement in bum patients. J Lab Clin Med 1984;103:284-93.
21. Gutteberg TJ, Haneberg B, Jorgensen T. The latency of serum acute proteins in meningococcal septicaemia, with special emphasis on lactoferrin. Clin Chim Acta 1984; 136:173-8.
22. Lash JA, Coates TD, Lafuze J, Baehner RL, Boxer LA. Plasma lactoferrin reflects granulocyte activation in vivo. Blood 1983;61:885-8.
23. Neyts J, Snoeck R, Schols D, et al. Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology 1992;189:48-58.
24. Kari B, Gehrz R. A human cytomegalovirus glycoprotein complex designated gC-TI is a major heparin-binding component of the envelope. J Virol 1992;66:1761-4.
25. Kari B, Gehrz R. Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II. J Gen Virol 1993;74:255-64.
26. Compton T, Nowlin DM, Cooper NR. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 1993;193:834-41.
27. Cooper NR, Nowlin DM, Taylor HP, Compton T. Cellular receptor for human cytomegalovirus. Transplant Proc 1991;23:56-9.
28. Nowlin DM, Cooper NR, Compton T. Expression of a human cytomegalovirus receptor correlates with infectibility of cells. J Virol 1991;65:3114-21.
29. Sodcrberg C, Giugni TD, Zaia JA, Larsson S, Wahlberg JM, Mbller E. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol 1993;67:6576-85.
30. Compton T, Nepomuceno RR, Nowlin DM. Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 1992;191:387-95.
31. Hosoya M, Neyts J, Yamamoto N, et al. Inhibitory effects of polycations on the replication of enveloped viruses (HIV, HSV, CMV, RSV, influenza A virus and togaviruses) in vitro. Antiviral Chem Chemother 1991;2:243-8.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265 75.
33. Habeeb AFSA. Detennination of free amino groups in proteins by trinitro-benzenesulfonic acid. Anal Biochem 1966;14:328-36.
34. Pless DP, Lennarz WJ. Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci USA 1977;74:134-8.
35. Dubois M, Gilles KA, Hamilton JK, et al. Colorimetric method for determination of sugars and related substances. Anal Chem 1956;28:350-6.
36. Mazeron MC, Jahn G, Plachter B. Monoclonal antibody E-13 (M-810) to human cytomegalovirus recognizes an epitope encoded by exon 2 of the major immediate early gene. J Gen Virol 1992;73:2699-703.
37. Plachter B, Nordin M, Wirgart BZ, et al. The DNA-binding protein P52 of human cytomegalovirus reacts with monoclonal antibody CCH2 and associates with the nuclear membrane at late times after infection. Vims Res 1992;24:265-76.
38. Grefte JMM, Van der Gun BTF, Schmolke S, et al. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol 1992;73:2923-32.
39. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203-10.
40. Miyoshi I, Taguchi H, Kubonishi I, et al. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr Cancer Res 1982;28:219-28.
41. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-21.
42. Metz-Boutigue MHS. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 1984;145:659-76.
43. Goodman RE, Schanbacher FL. Bovine lactoferrin mRNA: sequence, analysis and expression in the mammary gland. Biochem Biophys Res Commun 1991;180:75-84.
44. Pierce A, Colavizza D, Benaisssa M, et al. Molecular cloning and sequence analysis of bovine lactotransferrin. Eur J Biochem 1991;196:177-84.
45. Powell MJ, Ogden JE. Nucleotide sequence of human lactoferrin cDNA. Nucleic Acids Res 1990; 18:4013.
46. Rey MW, Woloshuk SL, deBoer HA, Pieper FR. Complete nucleotide sequence of human mammary gland lactoferrin. Nucleic Acids Res 1990; 18:5288.
47. Gislason J, Iyer S, Hutchens TW, Lonnerdal B. Lactoferrin receptors in piglet small intestine: lactoferrin binding properties, ontogeny, and regional distribution in the gastrointestinal tract. J Nutrition Biochem 1993;4:528-33.
48. Iyer S. Lactoferrin, lactoferrin receptors and iron metabolism. Eur J Clin Nutr 1993;47:232-41.
49. Zou S. Heparin-binding properties of lactoferrin and lysozyme. Comp Biochem Physiol [B] 1992;103:889-95.
50. Baynes RD, Bezwoda WR, Khan Q. Mansoor N. Plasma lactoferrin content: differential effect of steroid administration and infective illnesses: lack of effect of ambient temperature at which specimens are collected. Scand J Haematol 1986;37:353-9.
51. Delgado C, Francis GE, Fisher D. The uses and properties of peg-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249-304.
52. Stagno S, Reynolds DW, Pass RF, Alford CA. Breast milk and the risk of cytomegalovirus infection. N Engl J Med 1980;302:1073-6.
53. Dworsky M, Yow M, Stagno S, Pass RF, Alford C. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics 1983;72:295-9.
54. Welsh JK, May JT. Anti-infective properties of breast milk. J Pediatr 1979;94:1-9.
55. Grefte M, Blom N, Van der Giessen M, Van Son W, The TH. Ultrastruc-tural analysis of circulating cytomegalic cells in patients with active cytomegalovirus infections: evidence for vims production and endothelial origin. J Infect Dis 1993; 168:1110-8.